Anne Wojcicki's nonprofit wins bid for genetic testing company 23andMe
A nonprofit controlled by Anne Wojcicki, former chief executive of 23andMe, has won the bidding process to buy the bankrupt genetic testing company.
If approved by the court, the sale would put Wojcicki back at the helm of the company she co-founded and previously attempted to take private.
23andMe, which helped popularize at-home DNA test kits and was once valued at $6 billion, declared Chapter 11 bankruptcy in March.
The potential sale of the company has raised questions over privacy standards for genetic data, which experts say is uniquely sensitive, immutable and irreplaceable if stolen.
Read more: 'People should be worried': 23andMe bankruptcy could expose customers' genetic data
More than 11 million customers have given DNA samples to 23andMe, putting a trove of genetic information under the company's control.
Wojcicki's nonprofit TTAM Research Institute agreed to comply with 23andMe's privacy policy and committed to adopting additional consumer protections, according to a 23andMe statement. TTAM has offered $305 million to buy 23andMe and the company's assets.
'I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said in a statement. "We believe it is critical that individuals are empowered to have choice and transparency with respect to their genetic data."
Read more: States sue to block the sale of genetic data collected by DNA testing company 23andMe
New York-based drug maker Regeneron Pharmaceuticals was poised to buy 23andMe before the bankruptcy judge reopened the bidding process to allow for a bid from TTAM. The final round of bidding was conducted by the U.S. Bankruptcy Court for the Eastern District of Missouri and concluded when Regeneron declined to make a higher bid.
Dozens of states have filed a joint lawsuit against 23andMe to block the South San Francisco-based company's sale of its customers' genetic data without explicit consent.
'This isn't just data — it's your DNA,' said Oregon Atty. Gen. Dan Rayfield in a statement. 'People did not submit their personal data to 23andMe thinking their genetic blueprint would later be sold off to the highest bidder.'
Sign up for our Wide Shot newsletter to get the latest entertainment business news, analysis and insights.
This story originally appeared in Los Angeles Times.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
an hour ago
- Yahoo
Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why
Oscar Health, Inc. (NYSE:OSCR) is one of the Oscar Health extended its winning streak to a fourth consecutive day on Friday, jumping 13.05 percent to close at $21.22 apiece as investor sentiment was influenced by the previous days' surge. During the shortened, four-day trading week, shares of Oscar Health, Inc. (NYSE:OSCR) already grew by 52 percent, with analysts pointing to meme trading as having buoyed its share prices. Additionally, investor sentiment was supported by a new proposal for Medicare that would allow individuals and employers to enroll in a new version called 'Part E.' A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. While this would heighten competition with private insurers such as Oscar Health, Inc. (NYSE:OSCR), the voluntary enrollment could potentially delay or prevent Medicare's sooner-than-expected insolvency. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why
Oscar Health, Inc. (NYSE:OSCR) is one of the Oscar Health extended its winning streak to a fourth consecutive day on Friday, jumping 13.05 percent to close at $21.22 apiece as investor sentiment was influenced by the previous days' surge. During the shortened, four-day trading week, shares of Oscar Health, Inc. (NYSE:OSCR) already grew by 52 percent, with analysts pointing to meme trading as having buoyed its share prices. Additionally, investor sentiment was supported by a new proposal for Medicare that would allow individuals and employers to enroll in a new version called 'Part E.' A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. While this would heighten competition with private insurers such as Oscar Health, Inc. (NYSE:OSCR), the voluntary enrollment could potentially delay or prevent Medicare's sooner-than-expected insolvency. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
